Document is current
Any future updates will be listed below
-
Authors
Lesueur, Paul https://orcid.org/0000-0002-6200-845X
Lequesne, Justine
Grellard, Jean-Michel
Dugué, Audrey
Coquan, Elodie
Brachet, Pierre-Emmanuel
Geffrelot, Julien
Kao, William
Emery, Evelyne
Berro, David Hassanein
Castera, Laurent
Goardon, Nicolas
Lacroix, Joëlle
Lange, Marie
Capel, Aurélie
Leconte, Alexandra
Andre, Benoit
Léger, Angélique
Lelaidier, Anaïs
Clarisse, Bénédicte
Stefan, Dinu
-
Funding
Funding for this research was provided by:
Programme hospitalier de recherche clinique (PHRC-K15-135)
AstraZeneca (0)
- License Information
-
More Information
Article History
Received: 26 November 2018
Accepted: 27 February 2019
First Online: 4 March 2019
Ethics approval and consent to participate
: This study has received ethical approval from the <i>Comité de Protection des Personnes Nord Ouest III</i> in December 2016 (N° EudraCT: 2016–003468-38) and from National Agency for Medical and Health products Safety (Reference: 160589A-12) in March 2017. All patients will give their written informed consent before any study-related assessment start.
: Not applicable.
: Astra-Zeneca provided olaparib.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
